Central Oxytocinergic Neurotransmission: A Drug Target for the Therapy of Psychogenic Erectile Dysfunction

E-ISSN： 1873-5592|4|1|55-66

ISSN： 1389-4501

Source： Current Drug Targets, Vol.4, Iss.1, 2003-01, pp. : 55-66

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gene therapy for erectile dysfunction

By Mills Jesse N Dall’’Era Joseph E Carlsen Soren N Koul Hari Meacham Randall B

Pharmacogenomics, Vol. 8, Iss. 8, 2007-08 ,pp. : 979-984

Future Medicine

Access to resources Recommend Favorite

Update on Drug Interactions With Phosphodiesterase-5 Inhibitors Prescribed as First-Line Therapy for Patients with Erectile Dysfunction or Pulmonary Hypertension

Current Drug Metabolism, Vol. 14, Iss. 2, 2013-02 ,pp. : 265-269

Bentham Science Publishers

Access to resources Recommend Favorite

Drug target central

By Harland Lee Gaulton Anna

Expert Opinion on Drug Discovery, Vol. 4, Iss. 8, 2009-08 ,pp. : 857-872

Informa Healthcare

Access to resources Recommend Favorite

Treatment of Erectile Dysfunction in Patients with Cardiovascular Disease: Guide to Drug Selection

By Graham Jackson

Drugs, Vol. 64, Iss. 14, 2004-01 ,pp. : 1533-1545

Adis International

Access to resources Recommend Favorite

Future Options for Combination Therapy in the Management of Erectile Dysfunction in Older Men

By Frank Sommer Udo Engelmann

Drugs & Aging, Vol. 21, Iss. 9, 2004-01 ,pp. : 555-564

Adis International

Access to resources Recommend Favorite